Treating metabolic syndrome with fenofibrate
AssigneeLupin Atlantis Holdings SA
InventorsRalph T. Doyle, Jr., Douglas F. Kling, Roelof M. L. Rongen, Keith S. Rotenberg
Life of this patent
Estimating the term…
Abstract
A method of treating metabolic syndrome in a human diagnosed with metabolic syndrome by administering a therapeutically effective amount of fenofibrate over a treatment period. The results can include identifying a human as not having clinical metabolic syndrome after treatment, as compared to having metabolic syndrome before treatment.
Claims40
A method for treating metabolic syndrome in a human, the method comprising:
- administering a therapeutically effective amount of fenofibrate to a human having metabolic syndrome, wherein a human has metabolic syndrome if the human has at least three characteristics selected from the group consisting of:
- (a) a waist circumference greater than 102 cm for men and greater than 88 cm for women;
- (b) a triglyceride level greater than 150 mg/dl;
- (c) an HDL-cholesterol level less than 40 mg/dl for men and less than 50 mg/dl for women;
- (d) a blood pressure greater than or equal to 130/85 mmHG;
- and
- (e) a fasting glucose level greater than 110 mg/dl,
- such that after said administering of fenofibrate the human no longer has at least three characteristics selected from the group consisting of (a), (b), (c), (d), and (e).
A method of lowering triglycerides and increasing HDL-cholesterol in a human, the method comprising administering a therapeutically effective amount of fenofibrate to said human, wherein said human has a triglyceride level greater than 150 mg/dl and an HDL-cholesterol level less than 40 mg/dl for men and less than 50 mg/dl for women, and wherein said human has at least one characteristic selected from the group consisting of:
- (a) a waist circumference greater than 102 cm for men and greater than 88 cm for women;
- (b) a blood pressure greater than or equal to 130/85 mmHG;
- and
- (c) a fasting glucose level greater than 110 mg/dl,
- such that after said administering of fenofibrate the human has a triglyceride level less than 150 mg/dl and an HDL-cholesterol level greater than 40 mg/dl for men and greater than 50 mg/dl for women and no longer has at least one characteristic selected from the group consisting of (a), (b), and (c).
A method for treating metabolic syndrome in a human, the method comprising:
- administering a therapeutically effective amount of fenofibrate to a human having metabolic syndrome, wherein a human has metabolic syndrome if the human has at least three characteristics selected from the group consisting of:
- (a) a waist circumference greater than 102 cm for men and greater than 88 cm for women;
- (b) a triglyceride level greater than 150 mg/dl;
- (c) an HDL-cholesterol level less than 40 mg/dl for men and less than 50 mg/dl for women;
- (d) a blood pressure greater than or equal to 130/85 mmHG;
- and
- (e) a fasting glucose level greater than 110 mg/dl;
- wherein the fenofibrate is administered as a composition comprising fenofibrate and wherein the composition contains a single surfactant.
A method for treating metabolic syndrome in a human, the method comprising:
- administering a therapeutically effective amount of fenofibrate to a human having metabolic syndrome, wherein a human has metabolic syndrome if the human has at least three characteristics selected from the group consisting of:
- (a) a waist circumference greater than 102 cm for men and greater than 88 cm for women;
- (b) a triglyceride level greater than 150 mg/dl;
- (c) an HDL-cholesterol level less than 40 mg/dl for men and less than 50 mg/dl for women;
- (d) a blood pressure greater than or equal to 130/85 mmHG;
- and
- (e) a fasting glucose level greater than 110 mg/dl;
- wherein the fenofibrate is administered as a composition comprising granules comprising a neutral core, a layer of fenofibrate surrounding the neutral core, and a layer of hydrosoluble binder surrounding the layer of fenofibrate, wherein the composition contains a single surfactant.
Dependencies are inferred from the claim text.